Table 1.
Biological activities of mono-aromatic steroids (4–27).
| No. | Dominated Biological Activity (Pa) * | Additional Predicted Activities (Pa) * |
|---|---|---|
| 4 | Ovulation inhibitor (0.942) Cardiovascular analeptic (0.924) Apoptosis agonist (0.750) |
Anti-hypercholesterolemic (0.871) Lipid metabolism regulator (0.788) Prostate disorders treatment (0.737) |
| 5 | Anti-hypercholesterolemic (0.894) Ovulation inhibitor (0.889) Anesthetic general (0.868) |
Respiratory analeptic (0.851) Acute neurologic disorders treatment (0.793) Prostate disorders treatment (0.729) |
| 6 | Anesthetic general (0.845) Ovulation inhibitor (0.832) |
Acute neurologic disorders treatment (0.822) Neuroprotector (0.815) |
| 7 | Anti-hypercholesterolemic (0.856) Ovulation inhibitor (0.847) Cardiovascular analeptic (0.842) |
Lipid metabolism regulator (0.788) Apoptosis agonist (0.750) Prostate disorders treatment (0.725) |
| 8 | Anti-hypercholesterolemic (0.885) Apoptosis agonist (0.801) |
Hepatic disorders treatment (0.739) Ovulation inhibitor (0.726) |
| 9 | Acute neurologic disorders treatment (0.871) Respiratory analeptic (0.843) Vasoprotector (0.811) |
Neuroprotector (0.785) Anesthetic general (0.753) Ovulation inhibitor (0.740) |
| 10 | Cardiovascular analeptic (0.882) Ovulation inhibitor (0.860) |
Respiratory analeptic (0.846) Acute neurologic disorders treatment (0.844) |
| 11 | Respiratory analeptic (0.879) Ovulation inhibitor (0.765) |
Neuroprotector (0.762) Cardiovascular analeptic (0.692) |
| 12 | Acute neurologic disorders treatment (0.849) Vasoprotector (0.795) |
Anti-inflammatory (0.788) Ovulation inhibitor (0.778) |
| 13 | Psychotropic (0.815) Ovulation inhibitor (0.586) |
Attention deficit/hyperactivity disorder treatment (0.744) |
| 14 | Postmenopausal disorders treatment (0.945) | Anti-inflammatory (0.669) |
| 15 | Lipid metabolism regulator (0.913) Cytostatic (0.891) Anti-neoplastic (0.876) |
Hepatoprotectant (0.845) Immunosuppressant (0.792) Apoptosis agonist (0.784) |
| 16 | Chemopreventive (0.919) Proliferative diseases treatment (0.914) |
Anti-neoplastic (0.837) Vasoprotector (0.824) |
| 17 | Apoptosis agonist (0.893) Anti-neoplastic (0.827) |
Anti-inflammatory (0.873) Hypolipemic (0.854) |
| 18 | Apoptosis agonist (0.883) Anti-neoplastic (0.826) |
Hypolipemic (0.863) Anti-inflammatory (0.855) |
| 19 | Anti-neoplastic (0.879) Apoptosis agonist (0.775) |
Immunosuppressant (0.744) Anti-inflammatory (0.715) |
| 20 | Anti-neoplastic (0.782) | Genital warts treatment (0.736) |
| 21 | Apoptosis agonist (0.896) Anti-neoplastic (0.843) |
Hypolipemic (0.850) Anti-inflammatory (0.814) |
| 22 | Chemopreventive (0.887) Anti-neoplastic (0.794) |
Anti-inflammatory (0.819) Proliferative diseases treatment (0.784) |
| 23 | Anti-neoplastic (0.909) Apoptosis agonist (0.790) |
Anti-inflammatory (0.822) Immunosuppressant (0.727) |
| 24 | Anti-neoplastic (0.888) Apoptosis agonist (0.847) |
Anti-inflammatory (0.830) Immunosuppressant (0.739) |
| 25 | Anti-neoplastic (0.802) Apoptosis agonist (0.789) |
Anti-inflammatory (0.786) Prostate disorders treatment (0.685) |
| 26 | Acute neurologic disorders treatment (0.867) Anti-neoplastic (0.812) |
Diuretic (0.813) Male reproductive dysfunction treatment (0.759) |
| 27 | Anti-hypercholesterolemic (0.959) | Anti-neoplastic (0.832) |
* Only activities with Pa > 0.7 are shown. The main biological activity has a value where Pa is more than 0.7.